title: [Applications of monitoring human leukocyte antigen G and its inhibitory receptors in post-renal transplantation].
abstract: OBJECTIVE
  to study the feasibility of human leucocyte antigen-G (HLA-G) as a post-transplantation prognostic biomarker and discuss the correlation of its receptor expression and the mechanisms.
  
  
  METHODS
  a total of 215 recipients in our centre from February 2006 to June 2008 were divided into stable kidney function group (n = 173) and acute rejection group (n = 42). The soluble human leucocyte antigen-G5 (sHLA-G5) level in peripheral plasma was detected by ELISA. And the HLA-G receptor ILT-2, KIR2DL4 on T, B, NK lymphocytes were analyzed by flow cytometry (FCM). The sHLA-G5 cutoff level by ROC curve was employed to predict the events of acute post-transplantation rejection. And regression analysis was used to determine the association of sHLA-G5 with acute rejection.
  
  
  RESULTS
  an optimal cutoff value of 139.0 microg/L could be defined for sHLA-G5 (sensitivity: 63.6%, specificity: 82.1%, AUC: 0.780). Binary regression analysis showed that sHLA-G5 played an independent role on acute rejection (P = 0.019, OR = 0.039, 95%CI: 2.091 - 5.661). The rate of HLA-G receptor ILT-2 on CD4(+)T cell, CD8(+)T cell and B cell in acute rejection group was statistically lower than that in stable kidney function group (21% ± 7% vs 52% ± 17%, 23% ± 6% vs 39% ± 16%, 21% ± 7% vs 39% ± 16%, all P < 0.05). The expression of KIR2DL4 on NK cells in acute rejection group was statistically lower than that in stable kidney function group (31% ± 10%vs 57% ± 21%, P < 0.05).
  
  
  CONCLUSIONS
  sHLA-G5 level may be predicted for acute rejection with a high sensitivity and specificity. The up-regulated expression of ILT-2 and KIR2DLT may contribute to immunology tolerance in peripheral circulation.
authors.affiliation: Basic Research Lab, Organ Transplant Center, No. 309 Hospital of PLA, Beijing 100091, China.
authors.forename: Li
authors.initials: L
authors.lastname: XIAO
authors.forename: Bing-yi
authors.initials: BY
authors.lastname: SHI
authors.forename: Yu
authors.initials: Y
authors.lastname: GAO
authors.forename: Ming
authors.initials: M
authors.lastname: CAI
authors.forename: Ye-yong
authors.initials: YY
authors.lastname: Qian
authors.forename: Xiu-yun
authors.initials: XY
authors.lastname: HE
authors.forename: Xiao-guang
authors.initials: XG
authors.lastname: XU
authors.forename: Yong
authors.initials: Y
authors.lastname: HAN
authors.forename: Wen-qiang
authors.initials: WQ
authors.lastname: ZHOU
authors.forename: Xiao-yun
authors.initials: XY
authors.lastname: MENG
authors.forename: Meng-xia
authors.initials: MX
authors.lastname: HAN
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis / Q000276:immunology; D005260:Female; D006085:Graft Survival; D006680:HLA Antigens / Q000032:analysis / Q000276:immunology*; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I / Q000032:analysis / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D016030:Kidney Transplantation / Q000276:immunology*; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D008297:Male; D008875:Middle Aged; D011971:Receptors, Immunologic / Q000032:analysis / Q000276:immunology*; D054345:Receptors, KIR2DL4 / Q000032:analysis / Q000276:immunology; D054346:Receptors, KIR2DL5; D012680:Sensitivity and Specificity
chemical_list: D015703:Antigens, CD; D006680:HLA Antigens; D059951:HLA-G Antigens; D015395:Histocompatibility Antigens Class I; C515079:KIR2DL4 protein, human; C105299:LILRB1 protein, human; D000075362:Leukocyte Immunoglobulin-like Receptor B1; D011971:Receptors, Immunologic; D054345:Receptors, KIR2DL4; D054346:Receptors, KIR2DL5